Drug manufacturer Pfizer today stiffened its conditions on 340B sales to hospitals of the immunosuppressant Xeljanz, one of its top-selling products.
Starting May 1, Pfizer will let hospitals without an in-house pharmacy designate just one contract pharmacy for Xeljanz. Pfizer
…
U.S. Health and Human Services Secretary Xavier Becerra said today that the 340B program “doesn’t have the transparency we need” and “we are going to do what we can to make it more transparent.”
Becerra was asked about the drug
…
Drug manufacturer AbbVie this morning significantly tightened its restrictions on 340B pricing for hospitals.
AbbVie has not yet responded to a request for comment about the changes. Non-hospital covered entities continue to be exempt from AbbVie’s pricing restrictions.
Drug manufacturers
…
The 340B program was discussed at length today during a U.S. House subcommittee hearing on price transparency and consolidation in health care, with three Republicans questioning whether hospitals are abusing the program and two Democrats and a Republican cautioning against
…
Biopharmaceutical manufacturer Amgen this afternoon significantly expanded its conditions on 340B pricing when hospitals use contract pharmacies.
Johnson & Johnson announced a similar expansion of its 340B contract pharmacy limits last month. Hospital groups slammed J&J’s new restrictions.
Amgen’s
…
A large HIV/AIDS health care group, a Democratic 340B provider ally in Congress, and three national hospital groups lambasted community health centers and drug makers’ historic announcement yesterday that they are working together to remake the 340B program. Other 340B
…
The 340B program—and whether it needs change, protection, or both—came up often today during a U.S. Senate hearing on federal funding of community health centers.
The bulk of health centers’ federal grant funding—about $5.8 billion annually from the U.S. Health
…
Two of three judges on a federal appeals court panel yesterday repeatedly asked lawyers during a highly anticipated hearing in Washington, D.C., what standard the court should use to decide whether drug manufacturers’ 340B contract pharmacy conditions are legal.
The
…
Lawyers for federal healthcare officials told a federal district court yesterday that the government opposes a South Carolina health center’s efforts to have the longstanding 340B program definition of patient declared illegal.
In papers filed Sept. 22 in federal district court
…*Sign up for news summaries and alerts from 340B Report